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Multiple sclerosis (MS), a chronic immune-mediated 
disorder of the central nervous system, is character-
ised by inflammation, demyelination, oligodendro-
cyte death and neuronal loss.1 Its disease course is 
variable, but most patients present with a relapsing–
remitting form.2 Various natural history studies 
showed that male gender, late age of onset, shorter 
interval between first and second relapses, incomplete 
recovery from the first relapse and frequent relapses 
in the first 2 years following symptom onset were 
associated with poor prognosis.3–8 Higher Disability 
Status Scale (DSS) scores at the second and fifth year 
from disease onset, denoting early accumulation of 
disability, has also been associated with worse prog-
nosis.4–8 Therefore, MS seems to set its trajectory 
early in its course. In addition, clinical and radiologi-
cal disease activity in the infratentorial region of the 
brain and in the spinal cord has found to be a poor 
prognostic factor.9,10
A small proportion of patients with MS have an 
extremely active disease with early accumulation of 
fixed disabilities being the hallmark of their disease 
course. Various terms have been used to describe this 
phenotype, including ‘aggressive’, ‘malignant’ and 
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Abstract
Background:: Autologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment 
for patients with multiple sclerosis (MS) who have highly active disease, despite the use of standard 
disease-modifying therapies (DMTs). However, the optimal time for offering AHSCT to patients with 
‘aggressive’ MS is yet to be established.
Objectives:: The objective was to explore the safety and efficacy of AHSCT as a first-line DMT in 
patients with ‘aggressive’ MS.
Methods:: All patients with ‘aggressive’ MS who received AHSCT as a first-line DMT in five European 
and North American centres were retrospectively evaluated.
Results:: Twenty patients were identified. The median interval between diagnosis and AHSCT was 5 
(1–20) months. All had multiple poor prognostic markers with a median pre-transplant Expanded Dis-
ability Status Scale (EDSS) score of 5.0 (1.5–9.5). After a median follow-up of 30 (12–118) months, 
the median EDSS score improved to 2.0 (0–6.5, p < 0.0001). No patient had further relapses. Three had 
residual magnetic resonance imaging (MRI) disease activities in the first 6 months post-transplant, but no 
further new or enhancing lesions were observed in subsequent scans.
Conclusion:: AHSCT is safe and effective as a first-line DMT in inducing rapid and sustained remission 
in patients with ‘aggressive’ MS.
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‘fulminant’ MS. These patients do not respond ade-
quately to first-line disease-modifying therapies 
(DMTs) and should therefore be treated early with 
one of the higher efficacy DMTs, although a high pro-
portion of them do not respond optimally to these 
agents.11–16
Autologous haematopoietic stem cell transplantation 
(AHSCT) has gained considerable interest in recent 
years as an efficacious therapy for a selected group of 
patients with MS who have clinically and radiologi-
cally active disease, despite the use of standard 
DMTs.17 Treatment-related mortality has reduced sig-
nificantly in the last two decades through better 
patient selection, optimisation of transplant technique 
and increased centre experience.18–20 To date, there 
have been no published studies assessing the safety 
and efficacy of AHSCT as a first-line therapy in 
patients with ‘aggressive’ MS, although a Swedish 
case series of 48 patients included four who were 
‘treatment naïve’ before receiving AHSCT.21 Here, 
we report the cumulative experience of five interna-
tional centres using AHSCT as a first-line DMT in 
patients with ‘aggressive’ MS.
Methods
Subjects and inclusion criteria
This is a retrospective study in which all patients with 
‘aggressive’ MS, as deemed by their treating clini-
cians, who underwent AHSCT as a first-line DMT in 
Sheffield (United Kingdom), Uppsala (Sweden), 
Ottawa (Canada), Chicago (United States) and 
Florence (Italy), were identified and included. The 
diagnosis of MS was made using the most contempo-
rary version of the McDonald criteria at the time. No 
pre-defined definition of ‘aggressive’ MS was used, 
but patients needed to have had clinical and radiologi-
cal features in keeping with aggressive clinical course 
with poor prognostic markers which led their clini-
cians treating them with AHSCT in preference to 
high-efficacy DMTs. No patient received any stand-
ard DMTs before AHSCT, which was therefore con-
sidered a first-line treatment. Retrospective review of 
the medical records was performed to gather demo-
graphic details, disease-related characteristics and 
outcome measurements.
Procedure
Peripheral blood stem cells were mobilised with cyclo-
phosphamide (2–4.5 g/m2) and granulocyte colony-
stimulating factor (5–10 µg/kg/day). The following 
transplantation regimens were used based on centre 
preference: (1) busulfan, cyclophosphamide 200 mg/kg 
and rabbit anti-thymocyte globulin 6 mg/kg (Bu-Cy-
ATG) with CD34-selected autograft; (2) BCNU (car-
mustine) 300 mg/m2, etoposide 800 mg/m2, cytosine 
arabinoside 800 mg/m2, melphalan 140 mg/m2 and rab-
bit anti-thymocyte globulin 7.5–10 mg/kg (BEAM-
ATG) with unmanipulated autograft; or (3) 
cyclophosphamide 200 mg/kg and rabbit anti-thymo-
cyte globulin 6–7.5 mg/kg (Cy-ATG) with unmanipu-
lated autograft. Detailed descriptions of the transplant 
procedures had previously been published.21–23
Outcome measurements and statistical analysis
Treatment outcome was assessed using no evidence 
of disease activity (NEDA), defined as the absence of 
clinical relapses, confirmed disability progression and 
magnetic resonance imaging (MRI) disease activity.24 
Relapse was defined as new or worsening symptoms 
lasting for ⩾24 hours with objective signs confirmed 
on neurological examination. For the purpose of this 
analysis, MRI studies which were performed within 
the first 6 months post-AHSCT were used as re-base-
line images.24 Disability was measured using the 
Kurtzke Expanded Disability Status Scale (EDSS) 
score.25 Confirmed disability progression was defined 
as an increase in the EDSS score of ⩾1.0 point from 
the baseline (last EDSS before AHSCT) if the base-
line EDSS was ⩽5.5 points, or an increase of ⩾0.5 
point if the baseline EDSS was >5.5 points, which 
persisted over a 12-month period. The Wilcoxon 
signed-rank test was used to assess statistical differ-
ence between the median EDSS score at the baseline 
and the last follow-up post-AHSCT.
Results
A total of 20 patients with ‘aggressive’ MS who 
received AHSCT as a first-line DMT were identified 
from five centres (Table 1). There was an equal propor-
tion of male and female with a median age of 28 (17–
47) years at diagnosis and a median interval of 5 (1–20) 
months between diagnosis and treatment. The median 
last EDSS score before transplant was 5 (1.5–9.5). All 
patients had aggressive clinical course with multiple 
clinical and radiological features suggestive of poor 
prognosis, including multiple clinical relapses with 
incomplete recovery, high EDSS scores and numerous 
new, enlarging or gadolinium-enhancing MRI lesions 
on multiple occasions particularly in the brainstem, 
cerebellum and spinal cord (Tables 1 and 2).
Three conditioning regimens, Bu-Cy-ATG, BEAM-
ATG and Cy-ATG were used in 4, 4 and 12 patients, 
respectively, reflecting local treatment practices 
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(Table 2). Autologous stem cell re-infusions were 
unmanipulated in 16 patients, and CD34 selection 
was performed in the remaining 4 patients. The 
median follow-up period was 30 (12–118) months. 
Post-transplant median EDSS score at the last follow-
up appointment was 2.0 (0–6.5) (Table 2). The EDSS 
score of one patient did not change after the treat-
ment. Another patient had a transient increase, despite 
the overall improvement of their EDSS score follow-
ing AHSCT. None of these patients experienced con-
firmed disability progression (Figure 1(a) and (b)). 
EDSS scores of 13 patients plateaued after the initial 
6 months, whereas scores of 5 patients continued to 
improve beyond this period (Figure 1(a)). Median 
improvement of the EDSS score was 2.25 (0–6.5), 
which was statistically significant (p < 0.001, 
Wilcoxon signed-rank test) (Figure 1(b)). Subgroup 
analysis showed that this improvement was also sta-
tistically significant in males (p = 0.005) and females 
(p = 0.008), and in patients treated with the Cy-ATG 
conditioning regimen (p = 0.003) (Table 2).
Seventeen patients had no new, enlarging or gadolin-
ium-enhancing MRI lesions following AHSCT. Three 
patients had new lesions with or without gadolinium 
enhancement on their first MRI scans, which were 
performed within 6 months post-AHSCT; one had 
two new T2 lesions, one had a new T2 and a new gad-
olinium-enhancing lesions and one had a single new 
gadolinium-enhancing lesion. However, serial scans 
during their subsequent follow-ups (currently 23, 36 
and 84 months) did not show any new lesion or gado-
linium enhancement. Bu-Cy-ATG, BEAM-ATG and 
Cy-ATG were used as the conditioning regimen in 
one patient each. No clinical relapse following treat-
ment with AHSCT was seen in any of these 20 
patients. Overall, NEDA was 85% with a median fol-
low-up period of 30 (12–118) months, but 100% after 
re-baselining MRI disease activities to month 6 post-
transplant scans.
Expected transplant-related toxicities were reported, 
but there were no grade 4 toxicities or treatment-
related mortality (Table 3). Thyroid disorders were 
the only secondary autoimmune conditions that were 
observed in this cohort. In total, 20% of patients 
developed hypothyroidism or hyperthyroidism fol-
lowing AHSCT. There was no reported secondary 
malignancy. One female patient conceived naturally 
7 months after AHSCT and gave birth to a healthy 
baby. Another male patient’s partner conceived 
22 months after AHSCT and delivered a healthy baby.
Discussion
We present a small cohort of patients with multiple 
clinical and radiological features predictive of 
‘aggressive’ MS who received AHSCT as a first-line 
DMT. Aggressive clinical course, poor prognostic 
markers together with the lack of response to multiple 
courses of corticosteroids and plasma exchanges led 
their clinicians to treat them with AHSCT in prefer-
ence to high-efficacy DMTs. All patients were 
assessed and treated in centres experienced in using 
AHSCT to treat MS, and balanced therapeutic deci-
sions were made on an individual basis to proceed 
with this treatment.
There are no universally accepted diagnostic criteria 
which would allow an early prospective identification 
of patients with ‘aggressive’ MS. Rush et al.16 have 
recently suggested that ‘aggressive’ MS could be 
defined as relapsing–remitting MS with one or more 
of the following features: (1) EDSS score of 4 within 
5 years of disease onset, (2) two or more relapses with 
incomplete recovery in the past 12 months, (3) three 
or more MRI studies showing new or enlarging T2 
lesions or gadolinium-enhancing lesions despite treat-
ment and (4) unresponsive to one or more DMTs for 
up to 1 year. When these criteria were applied to our 
cohort retrospectively, 18 patients satisfied the 
Table 1. Demographic and disease-related characteristics.
Characteristics N
Median age at diagnosis (years) 28 (17–47)


















Median Pre-AHSCT EDSS score 5 (1.5–9.5)
AHSCT: Autologous haematopoietic stem cell 
transplantation; MRI: magnetic resonance imaging; EDSS: 
Expanded Disability Status Scale.
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definition of ‘aggressive’ MS at the time of their 
transplant. Although the remaining two patients did 
not fulfil these criteria, both had multiple poor 
prognostic markers, including large number of new 
and gadolinium-enhancing MRI lesions on multiple 
time points, leading their treating clinicians to offer 
AHSCT as a first-line therapy. Although a number of 
other definitions have been proposed for ‘aggressive’ 
MS, in clinical practice, this diagnosis is often made 
retrospectively.11,13,26,27 If the diagnosis of this pheno-
type is only made retrospectively, valuable time 
would be lost during which unsuccessful and some-
times futile therapeutic attempts would be made using 
standard DMTs, while disability will progress signifi-
cantly and become irreversible, potentially compro-
mising the feasibility, safety and efficacy of AHSCT 
at a later stage.
Although neuroinflammation and neurodegeneration 
occur concomitantly in MS, the initial relapsing–
remitting phase of this illness is thought to be driven 
by inflammation, whereas the late stage is dominated 
by neurodegeneration leading to a progressive neuro-
logical dysfunction with or without superimposed 
relapses.1 Various natural history studies have shown 
that disability progresses independent of relapses once 
a critical DSS/EDSS score is reached.4–8 It has been 
Table 2. Summary of treatment outcomes.
























 Male 10 30 (26–47) 5 (1–20) 5.5 (1.5–7.5) 5 (1.5–7.5) 2.5 (0–6.5) 30.5 (18–50)
 Female 10 25 (17–43) 4 (1–12) 7.5 (2–9.5) 5.5 (2–9.5) 1.5 (0 - 6.5) 27 (12–118)
Site
  Sheffield 
(United 
Kingdom)
7 31 (26–47) 6 (1–20) 5.5 (3–7.5) 5.5 (3–7.5) 3 (2.0–6.5) 24 (18–36)
  Uppsala 
(Sweden)
7 25 (19–31) 3 (1–5) 4.5 (2–8) 4.5 (2–8) 1 (0–2) 37 (12–118)
  Ottawa 
(Canada)
4 27 (20–43) 7 (5–12) 7 (6.5–9.5) 3 (2–6.5) 1.5 (1–4) 27 (24–50)
 Florence (Italy) 1 32 14 1.5 1.5 0 48
  Chicago 
(United States)
1 17 4 9.5 9.5 6.5 18
Conditioning regimen
 Bu-Cy-ATGa 4 27 (20–43) 7 (5–12) 7 (6.5–9.5) 3 (2–6.5) 1.5 (1–4) 27 (24–50)
 BEAM-ATGb 4 28 (25–32) 3 (1–14) 3 (1.5–8) 3 (1.5–8) 0.5 (0–1.5) 90.5 (48–118)
 Cy-ATGc 12 29 (17–47) 4 (1–20) 6 (2–9.5) 5.5 (2–9.5) 3 (0–6.5) 27 (12–37)
Total 20 28 (17–47) 5 (1–20) 6.5 (1.5–9.5) 5 (1.5–9.5) 2 (0–6.5) 30 (12–118)
AHSCT: Autologous haematopoietic stem cell transplantation; EDSS: Expanded Disability Status Scale; Bu: busulfan; Cy: 
cyclophosphamide; ATG: anti-thymocyte globulin; BEAM: BCNU, etoposide, cytosine arabinoside, melphalan.
aOnly used by Ottawa centre; bUsed by Uppsala and Florence centres; cUsed by Sheffield, Uppsala and Chicago centres.
Figure 1. Impact of AHSCT on disability progression. 
(a) Each line represents change in the EDSS score of one 
patient during the follow-up period. (b) The improvement 
of EDSS scores in our cohort.
J Das, JA Snowden et al.
journals.sagepub.com/home/msj 5
suggested that disability starts to accumulate once the 
intrinsic reserve capacity of the neural network is 
completely exhausted resulting in loss of its ability to 
make spontaneous recovery and improve its func-
tion.28 This disease model permits a ‘therapeutic win-
dow’ for treatment, suggesting that an early induction 
of disease remission would slow down disability accu-
mulation and may even allow the neural network to 
functionally recover to some extent. As the ‘therapeu-
tic window’ for the ‘aggressive’ MS is significantly 
narrower, a good case can be made for using AHSCT 
early in carefully selected patients rather than waiting 
for the first-line DMTs to fail and the disability to pro-
gress. Clearly, the risks of such intensive therapies 
with inherent potential toxicities need to be considered 
cautiously, even though such a strategy may pay long-
term dividends by potentially delaying the transition 
into the progressive phase and/or preventing irrevers-
ible disability. Given the relentless progression of dis-
ease that characterises ‘aggressive’ MS, it is important 
that there is at least discussion between neurologists 
and transplant haematologists about the management 
of such patients at an early stage in the course of their 
illness.
In this small cohort, overall cumulative NEDA was 
85% during a median follow-up period of 30 (12–118) 
months because three patients had MRI disease activ-
ity during the first 6 months post-transplantation 
before complete remission of the inflammatory pro-
cess was achieved. Following AHSCT, no patient had 
clinical relapse or confirmed disability progression. 
When MRIs were re-baselined at 6 months, the cumu-
lative NEDA rate was 100%, representing a steady-
state efficacy unconfounded by short-term disease 
activity carried over from the baseline. Moreover, 
AHSCT not only induced rapid remission but also 
improved EDSS scores in 95% of patients in keeping 
with an improvement of their functional status. 
Although high-efficacy DMTs are effective in reduc-
ing clinical and radiological disease activities in 
patients with relapsing–remitting MS, they have a 
limited impact on disability progression.29–31 Standard 
DMTs have also found to be less effective in people 
with high levels of disability.29–31
Our study had a number of limitations. Due to its ret-
rospective nature, the grading of adverse events was 
challenging, although there were no grade 4 toxici-
ties. However, it is important to note that despite the 
severe disability experienced by some patients who 
required intensive care for respiratory support, all tol-
erated the transplantation procedure and there was no 
treatment-related mortality. Furthermore, the number 
of patients included in this study was small, three dif-
ferent conditioning regimens were used and there was 
no control group. We were therefore unable to com-
pare the safety and efficacy of AHSCT as a first-line 
therapy with standard DMTs. Although a randomised 
controlled trial in treatment-naïve patients with 
‘aggressive’ MS comparing AHSCT against the best 
standard of care is needed, this will not be feasible 
owing to the relatively rare nature of this MS pheno-
type, and the fact that such patients’ clinical states 
evolve very rapidly which require timely individualised 
multi disciplinary team coordinated decision-making. 




 Febrile neutropenia (culture negative) 7
 Neutropenic sepsis 3
 Fever 3
 Mucositis 4
 Deep vein thrombosis 2
 Worsening fatigue 1
 Metabolic abnormalities  
  Hypophosphatemia 1
  Hypokalaemia 1
 Cardiovascular
  Atrial fibrillation 1
  Pre-syncope 1
  Myocarditis 1
 Liver
  Elevated transaminases 1
 Infection
  Urinary tract infection – Escherichia coli 2
  Clostridium difficile diarrhoea 1
   Lower respiratory tract infection (culture 
negative)
1
  Varicella zoster virus 1
   Sepsis (Streptococcus parasanguinis, 
Streptococcus salivarius, alpha-haemolytic 
streptococci or Enterobacter cloacae)
2
  Influenza 1
 Other  
  Lymphadenitis 1
  Low testosterone level 1
  Engraftment bone pain 1
  Rash 1
Delayed complications
 Secondary autoimmune conditions
  Hypothyroidism 3
  Graves’ disease 1
 Secondary malignancy 0
AHSCT: Autologous haematopoietic stem cell transplantation.
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Alternatively, a pragmatic treatment trial or a registry-
based study with well-defined criteria for ‘aggressive’ 
MS could help determining the best treatment 
approach, including patient selection and transplant 
technique, for this group of patients.
Conclusion
To the best of our knowledge, this is the largest cohort 
of patients with ‘aggressive’ MS who received 
AHSCT as a first-line DMT. The treatment was safe 
and highly effective in inducing rapid and sustained 
disease remission with a significant improvement of 
disability. Further studies are required to confirm 
these initial findings.
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